BR112022001814A2 - Métodos de tratamento de câncer multifocal - Google Patents

Métodos de tratamento de câncer multifocal

Info

Publication number
BR112022001814A2
BR112022001814A2 BR112022001814A BR112022001814A BR112022001814A2 BR 112022001814 A2 BR112022001814 A2 BR 112022001814A2 BR 112022001814 A BR112022001814 A BR 112022001814A BR 112022001814 A BR112022001814 A BR 112022001814A BR 112022001814 A2 BR112022001814 A2 BR 112022001814A2
Authority
BR
Brazil
Prior art keywords
cancer
multifocal
treatment methods
multifocal cancer
cancer treatment
Prior art date
Application number
BR112022001814A
Other languages
English (en)
Inventor
Paul Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of BR112022001814A2 publication Critical patent/BR112022001814A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

métodos de tratamento de câncer multifocal. as modalidades incluem métodos de tratamento (prevenção ou redução da incidência de) câncer multifocal por meio da administração a um foco de câncer unifocal de uma composição que compreende uma quantidade terapeuticamente eficaz de uma quantidade terapeuticamente eficaz de ingrediente farmaceuticamente ativo com capacidade de induzir necrose do tumor de câncer unifocal, em que a administração reduz a incidência de câncer multifocal, o grau de câncer multifocal e a progressão (piora) do câncer multifocal em todo o órgão ou organismo.
BR112022001814A 2019-07-31 2020-07-30 Métodos de tratamento de câncer multifocal BR112022001814A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/528,390 US11231421B2 (en) 2019-07-31 2019-07-31 Methods of treating multifocal cancer
PCT/US2020/044209 WO2021022015A1 (en) 2019-07-31 2020-07-30 Methods of treating multifocal cancer

Publications (1)

Publication Number Publication Date
BR112022001814A2 true BR112022001814A2 (pt) 2022-04-12

Family

ID=72088374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001814A BR112022001814A2 (pt) 2019-07-31 2020-07-30 Métodos de tratamento de câncer multifocal

Country Status (12)

Country Link
US (1) US11231421B2 (pt)
EP (1) EP4003533B1 (pt)
JP (1) JP2022542973A (pt)
KR (1) KR20220042155A (pt)
CN (1) CN114599395A (pt)
AU (1) AU2020321022A1 (pt)
BR (1) BR112022001814A2 (pt)
CA (1) CA3149097A1 (pt)
IL (1) IL290213A (pt)
MX (1) MX2022001227A (pt)
WO (1) WO2021022015A1 (pt)
ZA (1) ZA202201446B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205629A2 (en) * 2022-04-20 2023-10-26 The Penn State Research Foundation Use of androgen receptor-mediated mechanisms in the treatment of acute myeloid leukemia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457489A (en) 1981-07-13 1984-07-03 Gilmore Samuel E Subsea fluid conduit connections for remote controlled valves
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
CN1529613A (zh) 2001-03-08 2004-09-15 ��Ī��˹ҩƷ��˾ 使用神经丝蛋白治疗肿瘤和需要除去或破坏细胞的其它状况的方法
JP4584573B2 (ja) 2001-05-25 2010-11-24 ナイモックス コーポレーション 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
BR0211199A (pt) 2001-07-19 2004-10-26 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
SI1994152T1 (sl) 2006-02-28 2013-05-31 Nymox Corporation Peptidi uäśinkoviti pri zdravljenju tumorjev in ostalih stanj, ki zahtevajo odstranitev ali uniäśenje celic
US20070237780A1 (en) 2006-03-10 2007-10-11 Paul Averback Method of preventing or reducing the risk or incidence of cancer
US9243035B2 (en) 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US20160215031A1 (en) 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10532081B2 (en) * 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH

Also Published As

Publication number Publication date
IL290213A (en) 2022-03-01
KR20220042155A (ko) 2022-04-04
US20210033613A1 (en) 2021-02-04
AU2020321022A1 (en) 2022-03-03
US11231421B2 (en) 2022-01-25
WO2021022015A1 (en) 2021-02-04
CN114599395A (zh) 2022-06-07
JP2022542973A (ja) 2022-10-07
MX2022001227A (es) 2022-04-06
EP4003533A1 (en) 2022-06-01
CA3149097A1 (en) 2021-02-04
EP4003533B1 (en) 2024-03-13
ZA202201446B (en) 2024-01-31

Similar Documents

Publication Publication Date Title
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
EA202092154A1 (ru) Комбинированная терапия
SG10201902664RA (en) Combination therapy for treating cancer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2016090024A3 (en) Combination therapy for treatment of cancer
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
EA201991985A1 (ru) Конъюгаты антитело-лекарственное средство (калс) на основе ингибиторов гдац и применение в терапии
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
BR112022003126A2 (pt) Conjugado terapêutico
EA202190360A1 (ru) Комбинированная терапия